Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Assay Kit / ADA/PK Assay Elisa Kit

Drozitumab ELISA Kit

Catalog #:   KDA29103 Specific References (23) DATASHEET
Applications: Used for the quantitative determination of Drozitumab concentration in serum and plasma.
Sample type: Plasma, Serum
Sensitivity: 114.28 ng/mL
Range: 312.5 - 20,000 ng/mL
Overview

Catalog No.

KDA29103

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD262 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Drozitumab in the sample competitively binds to the pre-coated protein with biotin-labeled Drozitumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Drozitumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Drozitumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

312.5 - 20,000 ng/mL

Sensitivity

114.28 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

 

Intra-Assay Precision

Inter-Assay Precision

Sample

1

2

3

1

2

3

n

16

16

16

24

24

24

Mean (ng/mL)

10325.7

2732.3

1049.9

12014.0

2897.0

1062.2

Standard deviation

1075.6

89.9

53.7

2231.1

373.1

128.7

CV (%)

10.4

3.3

5.1

18.6

12.9

12.1

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

PRO95780, anti-DR5, rhuMAb DR5, CAS: 912628-39-8

Background

Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL). It was developed by Genentech as a drug for the treatment of cancers. This drug has been investigating in various trials for treating cancers including chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. The efficacy and selectivity of drozitumab in rhabdomyosarcoma (RMS) has been evaluated in preclinical models. And results showed that drozitumab is effective, in vitro, against the majority of RMS cell lines that express caspase-8 and, in vivo, may provide long-term control of RMS. In preclinical glioblastoma models, drozitumab has been found to induce apoptosis and colony formation in several glioblastoma cell lines combined with BV6 (combination index<0.1). A study about triple-negative breast cancer reported that drozitumab could induce apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes. The previous study about the treatment of pancreatic ductal adenocarcinoma has revealed that drozitumab could selectively eliminate CSCs, resulting in tumor growth inhibition and even regression of pancreatic tumors.

Data Image
  • Experiment Example
    CALCULATION OF RESULTS
    Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. Do not include the blank in the standard curve. The data may be linearized by plotting the log of the Drozitumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
References

Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer., PMID:39489464

Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma., PMID:31842413

Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma., PMID:28799237

Development of a bioassay as a measure of drozitumab-mediated apoptosis induced by soluble Fc gamma receptors., PMID:28506821

Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels., PMID:27409341

Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5., PMID:27330806

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis., PMID:27037412

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl., PMID:26759246

H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance., PMID:26136424

Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis., PMID:25880091

Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs)., PMID:25503127

Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway., PMID:24639349

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors., PMID:24101228

Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance., PMID:23885325

Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection., PMID:23771513

Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy., PMID:23670273

Death receptors as targets in cancer., PMID:23638798

TRAIL-based therapeutic approaches for the treatment of pediatric malignancies., PMID:23458616

Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer., PMID:23061802

Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response., PMID:21385927

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells., PMID:21251615

Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab., PMID:20179215

A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies., PMID:20145186

Datasheet

Document Download

Drozitumab ELISA Kit.pdf

 

$ 1128
Product specifications
96 T 1128

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Drozitumab ELISA Kit [KDA29103]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only